An estimated 2.5--3 billion persons live in tropical and subtropical regions where dengue virus (DENV) is transmitted ([@R1]--[@R3]). Absence of inexpensive and accurate tests to diagnose dengue makes case management, surveillance, and outbreak investigation difficult. During infection, immunoglobulin (Ig) M against DENV can often be detected ≈5 days after onset of fever ([@R4]*--*[@R6]). First-time (primary) DENV infections typically have a stronger and more specific IgM response than subsequent (secondary) infections, for which the IgM response is low compared with a strong IgG response. These patterns underscore the need for evaluating the performance of commercially available tests, especially for diagnosis of secondary DENV infections ([@R7]--[@R10]).

The Study
=========

To provide independent evaluation of dengue diagnostic tests, the United Nations International Children's Emergency Fund/United Nations Development Programme/World Bank/World Health Organization Special Programme for Research and Training in Tropical Diseases and the Pediatric Dengue Vaccine Initiative established a network of 7 laboratories based on criteria related to dengue expertise of the principal investigator, and type, capacity, management of the laboratory. The laboratories contributed serum specimens for the evaluation panel and conducted the evaluation. The 7 laboratories were located at Mahidol University (Bangkok, Thailand), Cho Quan Hospital (Ho Chi Minh City, Vietnam), Institut Pasteur (Phnom Penh, Cambodia), University of Malaya (Kuala Lumpur, Malaysia), Centers for Disease Control and Prevention (CDC) (San Juan, PR, USA), Instituto Medicina Tropical Pedro Kouri (Havana, Cuba), and Instituto Nacional Enfermedades Virales Humanas Dr. Julio I. Maiztegui (Buenos Aires, Argentina). Laboratories at Mahidol University and CDC acted as reference laboratories by providing samples for proficiency testing among laboratories and for assembling and validating the evaluation panel.

The evaluation panel consisted of 350 well-characterized serum specimens ([Table 1](#T1){ref-type="table"}). Specimens positive for IgM against DENV were obtained from patients with primary and secondary infections and represented all 4 DENV serotypes. IgM levels were determined by reference standard ELISAs developed by CDC and the Armed Forces Research Institute of Medical Science (Bangkok, Thailand) ([@R6],[@R7]). Positive samples were selected based on optical density (OD) and were weighted toward low and medium ODs. Negative control samples included serum samples from healthy persons in areas where dengue is not endemic and from patients with other flavivirus infections, febrile illness of other causes, or systemic conditions. Results were confirmed as negative for IgM antibodies against DENV by using predetermined reference standards. Additionally, 20 anti-DENV IgM-negative specimens were obtained from SeraCare Diagnostics (Milford, MA, USA). Panel specimens were coded, heat-inactivated, aliquoted, and lyophilized; 1 aliquot was retested by the reference laboratories after reconstitution.

###### Panels used for evaluation of 350 serum samples from patients with positive and negative results for IgM to DENV\*

  Evaluation panel                        No. samples
  --------------------------------------- -------------
  DENV IgM positive                       
  From primary infections                 27
  From secondary infections               154
  Total positive                          181†
  DENV IgM negative                       
  DENV positive/DENV IgM negative         19
  DENV IgG positive                       7
  Related flavivirus IgM positive         
  West Nile virus positive                25
  Yellow fever virus positive             4
  Related flavivirus IgG positive         
  West Nile virus positive                1
  Yellow fever virus positive             10
  St. Louis encephalitis virus positive   2
  Japanese encephalitis virus positive    10
  Febrile illness                         
  Lyme disease IgG positive               9
  Malaria                                 31
  New World hantavirus IgM positive       7
  Systemic conditions                     
  Rheumatoid factor                       6
  Systemic lupus erythematosus            2
  Healthy persons‡                        
  Negative                                36
  Total negative                          169

\*DENV, dengue virus; Ig, immunoglobulin. †No. serum samples identified as serotype specific: 26 DENV-1, 19 DENV-2, 13 DENV-3, and 7 DENV-4. Serotype was not identified for 116 samples. ‡From areas where dengue is not endemic.

Letters of interest and the evaluation protocol were sent to 20 dengue kit manufacturers. Six companies agreed to participate and provided 4 rapid diagnostic tests (RDTs) and 5 microplate ELISAs. Test characteristics are summarized in [Table 2](#T2){ref-type="table"}. Price per test ranged from US \$3 to \$15.

###### Characteristics of 9 tests used for detection of IgM against dengue virus\*

  ELISAs                                                                                                                                                                                                   
  ------------------------------- ---------------------------------------------------- ----------------------------- ------------------------------------------- ----------------------------------------- -----------------------------------------------
  Test name                       Dengue IgM capture                                   Pathozyme dengue M            Pathozyme dengue M capture                  Dengue fever virus IgM capture DxSelect   Dengue IgM capture
  Company, location               Panbio Diagnostics, Windsor, Queensland, Australia   Omega Diagnostics, Alva, UK   Omega Diagnostics                           Focus Diagnostics, Cypress, CA, USA       Standard Diagnostics, Kyonggi-do, South Korea
  Detection method                IgM capture                                          Indirect IgM detection        IgM capture                                 IgM capture                               IgM capture
  Format                          12 strips of 8 wells                                 12 strips of 8 wells          12 strips of 8 wells                        12 strips of 8 wells                      12 strips of 8 wells
  No. tests/package               96                                                   96                            96                                          96                                        96
  Antigen                         Recombinant DENV 1--4                                Purified DENV 2               DENV 1--4                                   DENV 1--4                                 DENV 1--4
  Sample volume, μL               10                                                   10                            20                                          10                                        10
  Total incubation time           130 min at 37°C                                      120 min at 37°C               110 min at 37°C                             240 min at room temperature               130 min at 37°C
  Storage conditions, °C          2--30                                                2--8                          2--8                                        2--8                                      2--8
  Rapid diagnostic tests                                                                                                                                                                                   
  Test name                       Dengue duo cassette                                  Hapalyse dengue-M PA kit      Dengucheck WB                               SD dengue IgG/IgM                         
  Company, location               Panbio Diagnostics                                   Pentax, Tokyo, Japan          Zephyr Biomedicals, Panaji, India           Standard Diagnostics                      
  Assay principle                 Lateral flow                                         Particle agglutination        Lateral flow                                Lateral flow                              
  Target antibody                 IgM and IgG                                          IgM                           IgM and IgG                                 IgM and IgG                               
  Format                          Cassette                                             12 strips of 8 wells          Cassette                                    Cassette                                  
  No. tests/package               25                                                   96                            25                                          25                                        
  Antigen                         Recombinant DENV 1--4                                DENV 1--4                     Recombinant DENV (serotype not specified)   Recombinant DENV 1--4 envelope protein    
  Specimen type                   Serum, plasma, or whole blood                        Serum or plasma               Serum, plasma, or whole blood               Serum or plasma                           
  Volume of sample required, μL   10                                                   1                             5                                           5                                         
  Duration of test, min           15                                                   90                            15                                          15--20                                    
  Storage conditions, °C          2--30                                                2--8                          4--30                                       1--30                                     
  Additional equipment required   No                                                   Yes (e.g., micropipette)      No                                          No                                        

\*Ig, immunoglobulin; DENV, dengue virus.

Laboratories evaluated the kits for sensitivity and specificity by using the evaluation panel. For each test, kappa coefficient values were determined to assess agreement of mean sensitivity and specificity of each test with the reference standard. A test of homogeneity was used to determine extent of agreement of results among sites.

Mean sensitivities of ELISAs were 61.5%--99.0%, and specificities were 79.9%--97.8% ([Figure 1](#F1){ref-type="fig"}, panels A and B). Tests from Panbio Diagnostics (Windsor, Queensland, Australia), Focus Diagnostics (Cypress, CA, USA), and Standard Diagnostics (Kyonggi-do, South Korea) showed significantly higher mean sensitivities (99.0%, 95% confidence interval \[CI\] 98.4%--99.5%; 98.6%, 95% CI 98.0%--99.2%; and 97.6%, 95% CI 96.8%--98.4%, respectively) than 2 tests from Omega Diagnostics (Alva, UK) (62.3% and 61.5%; p\<0.0001 for all comparisons). The Omega Pathozyme Capture test showed significantly higher mean specificity (97.8%, 95% CI 97.0%--98.6%) than the other ELISAs (79.9%--86.6%; p≤0.02 for all comparisons). The Focus, Panbio, and Standard ELISAs showed strong agreement with the reference standard (kappa values 0.81--0.85). Kappa values for Omega kits were below the acceptable range (0.46 and 0.59). Site-to-site variation for ELISAs was not significant (homogeneity \>0.05).

![A) Sensitivity and B) specificity of 5 microplate ELISAs used at laboratories in 7 countries for detecting immunoglobulin (Ig) M against dengue virus compared with reference solid-phase IgM antibody-capture ELISAs developed by the Centers for Disease Control and Prevention (Atlanta, GA, USA) and the Armed Forces Research Institute of Medical Science (Bangkok, Thailand). Mean sensitivities and specificities for the 5 tests are shown in parentheses. C) Sensitivity and D) specificity of 4 rapid diagnostic tests used at laboratories in 7 countries for detecting IgM against dengue virus compared with solid-phase IgM antibody-capture ELISAs. Mean sensitivities and specificities for the 4 tests are shown in parentheses.](08-0923-F1){#F1}

Mean sensitivities of RDTs were 20.5%--97.7%, and specificities were 76.6%--90.6% ([Figure 1](#F1){ref-type="fig"}, panels C and D). None had an acceptable kappa value for overall performance compared with reference methods. The Pentax (Tokyo, Japan) test had significantly higher mean sensitivity (97.7%, 95% CI 96.9%--98.5%) than all other RDTs (p\<0.0001 for all comparisons), but lowest mean specificity (76.6%, 95% CI 74.1%--79.0%; p\<0.0001 for all comparisons) and high false-positive rates for malaria and anti-DENV IgG specimens ([Figure 2](#F2){ref-type="fig"}). Panbio and Standard tests showed high mean specificities (90.6%, 95% CI 88.9%--92.3%, and 90.0%, 95% CI 88%.3--91.7%) with different mean sensitivities (77.8%, 95% CI 75.5%--80.1%, and 60.9%, 95% CI 58.2%--63.6%).

![Percentages of false-positive results for 4 rapid diagnostic tests (RDTs) (left panel) and 5 microplate ELISAs (right panel). Numbers of samples tested are shown in parentheses. Neg, negative; DEN, dengue; IgG, immunoglobulin G; WNV West Nile virus; YF, yellow fever; StLEnc, St. Louis encephalitis; JE, Japanese encephalitis; Lyme, Lyme disease; HTN, New World hantavirus; RF, rheumatoid factor; SLE, systemic lupus erythematosus.](08-0923-F2){#F2}

Conclusions
===========

This laboratory-based evaluation used a serum panel to determine the ability of 9 commercially available anti-DENV IgM tests to detect low levels of IgM and to determine specificity against pathogens that often cocirculate with DENV. Field trials are needed to determine the performance and utility of these tests in a local context.

Of the 5 ELISA kits evaluated, 3 (Focus, Panbio, and Standard) showed strong agreement with reference standard results and were consistent across all evaluation sites. Of concern are false-positive results shown by some tests on sera that were anti-DENV IgM negative but malaria positive, anti-DENV IgG positive, or rheumatoid factor positive. The laboratory at Mahidol University also tested the kits against 12 serum samples from patients with leptospirosis. The Panbio ELISA showed cross-reactivity with 58% of these samples, and the Focus ELISA showed cross-reactivity with 25%. Further studies are needed to elucidate the cause of this cross-reactivity.

Technicians were asked to score tests' user-friendliness. All RDTs scored higher than ELISAs, and the Panbio RDT scored highest.

Limitations of anti-DENV IgM tests include their inability to identify the infecting DENV type and potential antibody cross-reactivity with other flaviviruses ([@R11]*,*[@R12]). However, cross-reactivity to related viruses did not appear to be a problem with these tests. IgM tests can be useful for surveillance and support diagnosis of DENV infection in conjunction with clinical symptoms, medical history, and other epidemiologic information ([@R13]). Because IgM persists for [\>]{.ul}60 days, IgM assays should not be used in dengue-endemic countries as confirmatory tests for current illness. Presence of IgM indicates that a dengue infection has occurred in the past 2--3 months.

This evaluation has several limitations. Test performance was compared with reference laboratory assay results, which may be less sensitive than commercial assays, leading to some results being misclassified as false positive. Specificity of these tests may be higher in a field setting than in this evaluation because not all potential causes of false-positive results would be present. The panel consisted of a high proportion of specimens from persons with secondary DENV infections. Thus, the panel was weighted toward lower anti-DENV IgM levels. However, this feature reflects the situation in most dengue-endemic countries. Thus, tests that performed well against this panel could be expected to perform well in these diagnostic settings. We could not comprehensively evaluate whether the kits could detect primary infections with all 4 DENVs because all DENV types were not represented in the panel.

Data from this evaluation have been provided to the manufacturers and WHO member states. On the basis of these results, ELISAs from Focus, Panbio, and Standard Diagnostics will be included in the WHO Bulk Procurement Scheme. Technical discussions are ongoing to determine how tests might be improved to accelerate availability of useful methods for dengue case management, surveillance, and disease control.
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